Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
ChemoCentryx is planning to file a request with the U.S. Food and Drug Administration (FDA) by mid-year seeking approval of avacopan (CCX168) as a treatment for people with ANCA-associated vasculitis (AAV), the company ... Read more
Patients with granulomatosis with polyangiitis, a subtype of ANCA-associated vasculitis (AAV), have a higher rate of hospitalizations than the general population, a U.S. study reports. Their hospitalizations were also ... Read more
High-dose glucocorticoids — a type of corticosteroid hormone — are commonly prescribed as part of remission-induction therapy to people with ANCA-associated vasculitis (AAV) in Europe, a retrospective study reports. ... Read more
The U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of children ages two or older with granulomatosis with polyangiitis (GPA) ... Read more
In granulomatosis with polyangiits (GPA) patients, the levels of anti-neutrophil cytoplasmic autoantibodies (ANCAs) — the autoantibodies associated with the condition — appear to correlate with worse disease activity, a ... Read more
Almost half of patients diagnosed with ANCA-associated vasculitis (AAV) showed neurological symptoms in a single-site, retrospective study from India. But while nervous system involvement appears to be more common than ... Read more
ANCA-associated vasculitis (AAV) patients with renal involvement have higher blood levels of certain small vesicles than either patients without kidney symptoms or people without this disease, a study found. ... Read more